-+ 0.00%
-+ 0.00%
-+ 0.00%

Galmed partners with Tel Aviv University to test Aramchol in brain metastases

PUBT·04/14/2026 11:31:45
Listen to the news
Galmed partners with Tel Aviv University to test Aramchol in brain metastases
  • Galmed signed research collaboration agreement with Ramot at Tel Aviv University to evaluate brain-penetrant SCD1 inhibitor Aramchol as targeted therapy for metastatic brain cancer.
  • Program targets p53-deficient brain metastases based on TAU findings linking p53 inactivation to SCD1 upregulation that supports tumor growth in brain.
  • Work will use TAU 3D in vitro systems plus in vivo brain-metastasis models to assess Aramchol efficacy.
  • Collaboration aims to support Galmed oncology development strategy, including ongoing clinical work in colorectal cancer where p53 mutations are common.
  • Galmed said overall 2-year survival for brain metastasis remains below 10%, underscoring need for new targeted therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604140730PR_NEWS_USPR_____LN33663) on April 14, 2026, and is solely responsible for the information contained therein.